of p73 activity. The p53 mutant is a more potent inhibitor when it has arginine rather than proline at codon 72. Since Several reports have noted epidemiological differences in the prevalence or prognostic significance of p53 mutants p53 mutants with conformational changes are commonly with arginine (R) or proline (P) at the codon 72 polymorphrecessive (meaning they do not inactivate wild-type p53 in ism (R72/P72) in certain cancer types, but the biological a transdominant negative manner), we postulated that two significance of these variants is unclear. The ability of p53 functionally distinct pathways of p53 inactivation might exist: mutants to interact with and inactivate the p53 homolog an R72-dependent one for recessive alleles and an R72-p73 was recently reported to depend on the conformational independent one for dominant alleles. To test this theory we state of the p53 protein and the residue at codon 72. Since examined whether the mutant p53 allele in our series of the conformation of p53 mutants may influence their ability human cancers (15-17) was able to inhibit wild-type p53 to transdominantly inhibit wild-type p53, we tested whether transactivation in a yeast transdominance assay (18) and there was a correlation between the amino acid at codon analyzed the status of the codon 72 polymorphism by sequen-72 and the transdominance of p53 alleles found in tumors.
cing (19) ( Table I) . Since the TP53 mutations were originally The transdominance test was performed using a simple identified using a yeast p53 functional assay in which a large yeast transcription assay, and the amino acid at codon 72 fragment of p53 cDNA including codon 72 is cloned as a was determined by sequencing. A total of 100 p53 mutants single unit (18), we could readily determine the codon 72 were tested. Compared with the germline frequency (R:P sequence of the mutant p53 allele. ⍧ 427:297), an extreme bias in favor of the R72 allele was
We tested 97 missense mutations and three in-frame deletions observed with recessive mutants (R:P ⍧ 50:7, P < 0.0002), found in human cancers (39 brain tumors, eight liver cancers, whereas no selection for the R72 allele was seen with 11 colon cancers, 17 breast cancers, seven pancreatic cancers, transdominant mutants (R:P ⍧ 23:20). p53 and p73 are 17 oral cancers and one skin cancer). We excluded chainknown to transactivate overlapping sets of target genes.
terminating mutations (premature stop codon and frameshift We interpret the R72 bias with recessive mutants as mutations) from this study because such mutants cannot interact evidence that decreased activation of p53 target genes with the remaining wild-type p53 allele, due to the lack of the provides a selective growth advantage to tumor cells during C-terminal oligomerization domain at amino acids 324-355. the stage of tumorigenesis in which a wild-type and mutant
The spectrum of TP53 mutations studied here was essentially p53 allele coexist. We suggest that transdominant p53 identical to that in the IARC database (2), with respect to mutants achieve this by inactivation of the remaining wildfrequency of hotspot mutations, type of base changes (transition type p53 allele, whereas recessive p53 mutants achieve it versus transversion) and distribution of the mutations. Codon through inactivation of p73.
72 in the mutant alleles was arginine in 73 tumors and proline in 27. The R72 allele was thus significantly over-represented in the tumors compared with its germline frequency in the Japanese population (R:P ϭ 427:297, P Ͻ 0.008, χ 2 test) (20,21). This is consistent with the observation of Marin et al. Mutation of the TP53 tumor suppressor gene itself is seen in that mutant alleles containing R72 are preferentially selected more than half of all human cancers (1-3), and tumors retaining during tumorigenesis (14). Interestingly, examination of transwild-type p53 often have mutations elsewhere in the p53 dominance data revealed that this selection for R72 was true pathway or express viral proteins that inactivate p53 (4, 5) . A only of recessive mutant p53 alleles. There were 23 R72 and common polymorphism at residue 72 [Pro (P) or Arg (R)] has 20 P72 alleles in the transdominant group, compared with 50 been linked to the ability of p53 to interact with cellular R72 and only seven P72 alleles in the recessive group. Thus, proteins and its susceptibility to degradation by the human there is an extreme bias in the selection of alleles between the papillomavirus E6 protein, possibly through an effect of the two types of mutants (Table I ; P Ͻ 0.0002, χ 2 test). With polymorphism on the conformation of the p53 protein (6,7). Following the first report of an increased risk of cervical transdominant mutants, the frequency of the R72 allele (53%)
M.Tada et al. is close to the germline frequency (59%), suggesting that there tested, although the number of samples is too small to reach statistical significance (R72:P72 in brain tumors 23:2; oral is little, if any, selective advantage in retaining the R72 allele when the p53 mutant is transdominant. In contrast, with cancer 9:1; liver cancer 4:1; breast cancer 11:2; colon and pancreatic cancer, 4:0). recessive mutants, the frequency of the R72 allele (88%) is much higher than the germline frequency (59%), suggesting A simple model to explain this finding postulates that at the heterozygous stage in tumorigenesis a cell containing a that there is a strong advantage in retaining the R72 allele when the p53 mutant is recessive (P Ͻ 0.0002, χ 2 test). This transdominant mutant has reduced p53 activity, and consequently a growth advantage, irrespective of p73 activity. In bias was seen with recessive mutants in every tumor type perhaps explaining why it is so commonly found in tumors. In conclusion, our finding supports the model proposed by 
